Tag: FDA-approved lung cancer immunotherapy

Home / FDA-approved lung cancer immunotherapy

Categories

Neoadjuvant/adjuvant durvalumab is approved by the USFDA for resectable non-small cell lung cancer

August 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca) in combination with platinum-containing chemotherapy as a neoadjuvant treatment, fol...
fda-approved-lung-cancer-immunotherapy

Scan the code